These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 20093414)
1. WHO classification of myeloid neoplasms and leukemia. Wandt H; Haferlach T; Thiede C; Ehninger G Blood; 2010 Jan; 115(3):748-9; author reply 749-50. PubMed ID: 20093414 [No Abstract] [Full Text] [Related]
2. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Vardiman JW; Thiele J; Arber DA; Brunning RD; Borowitz MJ; Porwit A; Harris NL; Le Beau MM; Hellström-Lindberg E; Tefferi A; Bloomfield CD Blood; 2009 Jul; 114(5):937-51. PubMed ID: 19357394 [TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative neoplasms: an overview. Finnegan K Clin Lab Sci; 2011; 24(3):178-82. PubMed ID: 21905584 [No Abstract] [Full Text] [Related]
4. [Myeloproliferative neoplasms and related diseases]. Kirito K Rinsho Ketsueki; 2009 Mar; 50(3):134-46. PubMed ID: 19352079 [No Abstract] [Full Text] [Related]
5. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Vardiman J; Hyjek E Hematology Am Soc Hematol Educ Program; 2011; 2011():250-6. PubMed ID: 22160042 [TBL] [Abstract][Full Text] [Related]
6. [Review of changes introduced by the new WHO classification (4th edition) of myeloid neoplasms. An overview]. Komatsu N Rinsho Ketsueki; 2009 Mar; 50(3):127-33. PubMed ID: 19352078 [No Abstract] [Full Text] [Related]
7. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Cazzola M; Kralovics R Blood; 2014 Jun; 123(24):3714-9. PubMed ID: 24786775 [TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative neoplasms: the role of molecular markers. Collins L Clin Lab Sci; 2011; 24(3):183-6. PubMed ID: 21905585 [No Abstract] [Full Text] [Related]
9. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675 [TBL] [Abstract][Full Text] [Related]
11. Introduction to a review series on myeloproliferative neoplasms. Cazzola M Blood; 2017 Feb; 129(6):659. PubMed ID: 28028028 [No Abstract] [Full Text] [Related]
12. [Molecular bases of leukemia, MPD and MDS]. Kitamura T Rinsho Ketsueki; 2009 Mar; 50(3):174-81. PubMed ID: 19352084 [No Abstract] [Full Text] [Related]
14. The Diagnostic Work-Up of Hypereosinophilia. Wang SA Pathobiology; 2019; 86(1):39-52. PubMed ID: 29961056 [TBL] [Abstract][Full Text] [Related]
15. BCR-ABL1--negative myeloproliferative neoplasms: a review of molecular biology, diagnosis, and treatment. Vakil E; Tefferi A Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S37-45. PubMed ID: 22035746 [TBL] [Abstract][Full Text] [Related]
16. [Contribution of a hematologic cytogenetic laboratory to the diagnosis, classification and prognosis of various hematologic malignancies]. Debray J; Krulik M; Smadja NV Bull Acad Natl Med; 1992 May; 176(5):629-38; discussion 638-40. PubMed ID: 1422868 [TBL] [Abstract][Full Text] [Related]
17. [Recent advances in molecular pathogenesis of myeloproliferative neoplasms]. Ikeda K Rinsho Ketsueki; 2016 Feb; 57(2):156-64. PubMed ID: 26935633 [TBL] [Abstract][Full Text] [Related]